APRIL 26, 2024
Report from the Annual General Meeting
Key News
APRIL 17, 2024
Extended patent protection for OX640 in the US
April 2, 2024
Conditions for early redemption of existing bond fulfilled
Read all documents related to the refinancing of the existing bond - MARCH 2024
A commercial stage pharmaceutical company with three revenue generating pharmaceutical products
Development pipeline targeting large medical needs
AmorphOX® - a novel world leading nasal delivery technology leading to a new wave of products